ABO blood groups and thrombosis: A causal association, but is there value in screening?

Future Cardiology

Volumn 7, Issue 2, 2011, Pages 191-201

  Clark, Peter ^a   Wu, Olivia ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

ABO blood group; myocardial infarction; venous thrombosis; von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 7; BLOOD GROUP H ANTIGEN; LIPID; VON WILLEBRAND FACTOR;

ANTIGEN EXPRESSION; ARTERY THROMBOSIS; BLOOD CLOTTING TEST; BLOOD GROUP ABO SYSTEM; CARDIOVASCULAR RISK; GENE MUTATION; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; SCREENING; THROMBOPHILIA; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ABO BLOOD-GROUP SYSTEM; ERYTHROCYTES; HUMANS; INCIDENCE; MASS SCREENING; RISK FACTORS; THROMBOSIS; VON WILLEBRAND FACTOR; WORLD HEALTH;

EID: 79953748355     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.10.191     Document Type: Review

References (98)

1. Egeberg O: Inherited antithrombin deficiency causing thrombophilia. Thromb. Diath. Haemorrh. 13, 516-530 (1965).
2. Kyrle P, Erich Minar E, Hirschl M et al.: High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N. Engl. J. Med. 343, 457-462 (2000). Important paper demonstrating the link between factor VIII/von Willebrand factor (VWF) and recurrent thrombosis.
3. Christiansen S, Cannegieter S, Koster T, Vandenbroucke J, Rosendaal F: Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 293, 2352-2361 (2005). Useful overview on current knowledge of predicting those at risk of recurrent thrombosis after anticoagulant treatment.
4. Wu O, Bayoumi N, Vicker M, Clark P: ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. J. Thromb. Haemost. 6, 62-69 (2008). Comprehensive systematic review of the influence of ABO(H) on venous and arterial thrombosis.
5. Tirado I, Mateo J, Soria J et al.: The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism. Thromb. Haemost. 93 468-474 (2005).
6. Daniels G: Human Blood Groups (2nd Edition). Blackwell Science Ltd, Oxford, UK (2002).
7. O'Donnell J, Mille-Baker B, Laffan M: Human umbilical vein endothelial cells differ from other endothelial cells in failing to express ABO blood group antigens. J. Vasc. Res. 37, 540-547 (2000).
8. Oriol B, Mollicone R, Coullin P, Dalix A, Candelier J: Genetic regulation of the expression of ABH and Lewis antigens in tissues. APMIS Suppl. 27, 29-38 (1992). Comprehensive overview on what is currently known on the regulation of ABO(H) gene expression in a variety of tissues.
9. Sodetz J, Paulson J, McKee P: Carbohydrate composition and identification of blood group A, B, and H oligosaccharide structures on human factor VIII/von Willebrand factor. J. Biol. Chem. 254, 10754-10760 (1979).
10. Matsui T, Fujimura Y, Nishida S, Titani K: Human plasma a 2-macroglobulin and von Willebrand factor possess covalently linked ABO(H) blood group antigens in subjects with corresponding ABO phenotype. Blood 82, 863-868 (1993).
11. Wagner D, Marder V: Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localization. J. Cell. Biol. 99, 2123-2130 (1984).
12. Canis K, McKinnon T, Nowak A et al.: The plasma von Willebrand factor O-glycome comprises a surprising variety of structures including ABH antigens and disialosyl motifs. J. Thromb. Haemost. 8, 137-145 (2010).
13. Sarode J, Goldstein J, Sussman I, Nagel R, Tsai H: A and B blood group antigens are present on plasma (but not on platelet) von Willebrand factor and their removal decreases ristocetin co-factor activity. Blood 90, 435A (1997).
14. Brown S, Bowen D, Elis D, Collins P: von Willebrand factor ABO blood group associated antigens: immunological detection and distribution. Blood 90, 466A (1997).
15. Brown S, Collins P, Bowen D: Heterogeneous detection of A-antigen on von Willebrand factor derived from platelets, endothelial cells and plasma. Thromb. Haemost. 87, 990-996 (2002).
16. McCallum C, Peake I, Newcombe R et al.: Factor VIII levels and blood group antigens. Thromb. Haemost. 50, 757 (1983).
17. Orstavik K, Magnus P, Resiner H, Berg K, Graham J, Nance W: Factor VIII and factor IX in a twin population: evidence for a major effect of ABO locus on factor VIII level. Am. J. Hum. Genet. 37, 89-101 (1985).
18. Gill J, Endres-Brooks J, Bauer P, Marks W, Montgomery R: The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 69, 1691-1695 (1987).
19. Shima M, Fufimura Y, Nishiyama T et al.: ABO blood group genotype and plasma von Willebrand factor in normal individuals. Vox Sang. 68, 236-240 (1995).
20. Souto J, Almasy L, Muñiz-Diaz E et al.: Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time. Arterioscler. Thromb. Vasc. Biol. 20, 2024-2028 (2000).
21. O'Donnell J, Boulton F, Manning R, Laffan M: Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. Arterioscler. Thromb. Vasc. Biol. 22, 335-341 (2002). Important demonstration of influence of ABO(H)-like substance on VWF and VWF levels.
22. Sousa N, Anicchino-Bizzacchi J, Locatelli M, Castro V, Barjas-Castro M: The relationship between ABO groups and subgroups, factor VIII and von Willebrand factor. Haematologica 92, 236-239 (2007).
23. Schleef M, Erwin S, Dick A, Frank J, Schramm W, Spannagl M: Relationship between ABO and secretor genotype with plasma levels of factor VIII and von Willebrand factor in thrombosis patients and control individuals. Br. J. Haematol. 128, 100-107 (2005).
24. Morelli V, de Visser M, Vos H, Bertina R, Rosendaal F: ABO blood group genotypes and the risk of venous thrombosis: effect of factor V Leiden. J. Thromb. Haemost. 3, 183-185 (2005).
25. Trégouët D-A, Heath S, Saut N et al.: Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. Blood 113, 5298-5303 (2009).
26. Paiva S, Sabino A, Carvalho M et al.: Polymorphisms in exons 6 and 7 of the ABO locus and their association with venous thrombosis in young Brazilian patients. Blood Coag. Fibrinol. 20, 122-128 (2009).
27. Morelli V, de Visser M, van Tilburg N: ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens. Thromb. Haemost. 97, 534-541 (2007).
28. Brown S, Eldridge A, Collins P, Bowen D: Increased clearance of von Willebrand factor antigen post-DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process? J. Thromb. Haemost. 1, 1714-1717 (2003).
29. Sweeney J, Hoernig L: Intraplatelet von Willebrand factor and AO blood group. Thromb. Res. 69, 393-398 (1992).
30. Gallinaro L, Cattini M, Sztukowska M et al.: A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence von Willebrand factor. Blood 111, 3540-3545 (2008).
31. Bowen D: An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J. Thromb. Haemost. 1, 33-40 (2003).
32. O'Donnell J, McKinnnon T, Crawley J, Lane D, Laffan M: Bombay phenotype is associated with reduced plasma vWF levels and an increased susceptibility to ADAMTS13 proteolysis. Blood 106, 1988-1991 (2005).
33. Badirou I, Kurdi M, Rayes J et al.: von Willebrand factor clearance does not involve proteolysis by ADAMTS-13. J. Thromb. Haemost. 8, 2338-2340 (2010).
34. van Schooten C, Shahbazi S, Groot E et al.: Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood 112, 1704-1712 (2010).
35. Ohira T, Cushman M, Tsai M et al.: ABO blood group, other risk factors and incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE). J. Thromb. Haemost. 5, 1455-1461 (2007). Important longitudinal study of venous thromboembolism (VTE).
36. Clark P, Walker ID, Greer I: Acquired activated protein-C resistance in pregnancy and association with increased thrombin generation and fetal weight. Lancet 353, 292-293 (1999).
37. Clark P, Walker ID: The phenomenon known as acquired activated protein C resistance. Br. J. Haematol. 115, 767-773 (2001). Review of the mechanism and importance of acquired resistance to activated protein C.
38. Clark P, Sattar N, Walker I, Greer I: The Glasgow Outcome, APCR and Lipid (GOAL) Pregnancy Study: significance of pregnancy associated activated protein C resistance. Thromb. Haemost. 85, 30-35 (2001).
39. Favaloro E, Soltani S, McDonald J, Grezchnik E, Easton L: Activated protein C resistance: the influence of ABO-blood group, gender and age. Thromb. Res. 117, 665-670 (2006).
40. Clark P, Rosing J, Curvers J et al.: The Glasgow APC resistance and lipid (GOAL) pregnancy study: pregnancy associated APC resistance. Thromb. Haemost. 86(Suppl.), 3002 (2001).
41. Colonia V, Roisenberg I: Investigation of associations between ABO blood groups and coagulation, fibrinolysis, total lipids, cholesterol and triglycerides. Hum. Genet. 48, 221-230 (1979).
42. Fagerhol MK, Abildgaard U, Kornstad L: Antithrombin III concentration and ABO blood group. Lancet 1971, 664-665 (1971).
43. Rodeghiero F, Tosetto A: The VITA Project: population-based distributions of protein C, antithrombin III, heparin-cofactor II and plasminogen - relationship with physiological variables and establishment of reference ranges. Thromb. Haemost. 76, 226-233 (1996).
44. Stormorken H, Erikssen J: Plasma antithrombin III and factor VIII antigen in relation to angiographic findings, angina and blood groups in middle-aged men. Thromb. Haemost. 38, 874-880 (1977).
45. Jenkins P, O'Donnell J: ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? Transfusion 46, 1836-1844 (2006). Comprehensive review of VWF metabolism.
46. Langman M, Elwood P, Goote J, Ryrie D: ABO and Lewis blood groups and serum cholesterol. Lancet 2, 607-609 (1969).
47. Oliver M, Cumming R, Geigerova H: Serum cholesterol and ABO and Rhesus blood groups. Lancet 2(7621), 605-606 (1969).
48. Garrison R, Havlik R, Harris R, Feinleib M, Kannel W, Padgett S: ABO blood group and cardiovascular disease. The Framingham study. Atherosclerosis 25, 311-318 (1976).
49. Banerjee B, Saha N: Interrelation of serum cholesterols, ABO-Rh blood groups and body fat. Med. J. Malaysia 24, 41-44 (1969).
50. Cronenwett J, Davis J, Garrett E: ABO blood group and serum lipids in female atherosclerosis. J. Cardiovasc. Surg. 124, 658-661 (1983).
51. Horby J, Gyrtrup H, Grande P, Vestergaard A: Relation of serum lipoproteins and lipids to the ABO blood groups in patients with intermittent claudication. J. Cardiovasc. Surg. 30, 533-537 (1989).
52. Green D, Jarrett O, Ruth K, Folsom A, Liu K. Relationship among Lewis phenotype, clotting factors and other cardiovascular risk factors in young adults. J. Lab. Clin. Med. 125, 334-339 (1995).
53. Blann A, Daly RD, Amiral J: The influence of age, gender and ABO blood group on soluble endothelial cell markers and adhesion molecules. Br. J. Haematol. 92, 498-500 (1996).
54. Melzer D, Perry J, Hernandez D et al.: A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genet. 4, E1000072 (2008).
55. Paré G, Chasman D, Kellogg M et al.: Novel asociation of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women. PLoS Genet. 4, E1000118 (2008).
56. Clark P, Jordan F, Pearson C et al.: Intercellular adhesion molecule-1 (ICAM-1) expression is upregulated by thrombin in human monocytes and THP-1 cells in vitro and in pregnant subjects in vivo. Thromb. Haemost. 89, 1043-1051 (2003).
57. Heit J: The epidemiology of venous thromboembolism in the community. Arterioscler. Thromb. Vasc. Biol. 28, 370-372 (2008).
58. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM: A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88, 3698-3703 (1996). Description of the mutation.
59. Bertina RM, Koeleman BPC, Koster T et al.: Mutation in blood-coagulation factor-V associated with resistance to activated protein-C. Nature 369, 64-67 (1994). Description of the mutation.
60. Lijfering W, Rosendaal F, Cannegieter S: Risk factors for venous thrombosis - current understanding from an epidemiological point of view. Br. J. Haematol. 149, 824-833 (2010).
61. Robert A, Aillaud MF, Eschwege V, Randrianjohany A, Scarabin Y, Juhan-Vague I: ABO blood group and risk of venous thrombosis in heterozygous carriers of factor V Leiden. Thromb. Haemost. 83, 630-631 (2000).
62. Procare-GEHT group: ABO blood group but not haemostatic genetic polymorphisms significantly influence the thrombotic risk: a study of 180 homozygotes for the factor V Leiden mutation. Br. J. Haematol. 135, 697-702 (2006).
63. Jukic I, Bingulac-Popovic J, Dogic V et al.: ABO blood groups and genetic risk factors for thrombosis in Croatian population. Croatian Med. J. 50, 550-558 (2009).
64. Lima M, de Oliveira-FilhoI A, Campos J et al.: Increased risk of venous thrombosis by AB alleles of the ABO blood group and Factor V Leiden in a Brazilian population. Genet. Mol. Biol. 32, 264-267 (2009).
65. Miñano A, Ordóñez A, España F et al.: ABO blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms. Haematologica 93, 729-734 (2008).
66. Gonzalez OAJ, Medina RJM, Martin L, Alvarez V, Coto E: The O blood group protects against venous thromboembolism in individuals with the factor V Leiden but not the prothrombin (factor II G20210A) mutation. Blood Coagul. Fibrinol. 10, 303-307 (1999).
67. Canonico M, Olie V, Carcaillon L, Tubert-Bitter P, Scarabin P: Synergism between non-O blood group and oral estrogen in the risk of venous thromboembolism among postmenopausal women: the ESTHER study. Thromb. Haemost. 99, 246-248 (2008).
68. Smith E, Lowe F, Lee A, Rumley A, Leng G, Fowkes F: Smoking, hemoheologic factors and progression of peripheral arterial disease in patients with claudication. J. Vasc. Surg. 28, 129-135 (1998).
69. Blann A, McCollum C: Hemostatic risk factors in patients with vascular disease. Atherosclerosis 93, 255-256 (1992).
70. Woodburn K, Rumley A, Lowe GDO, Pollock JG: Thrombotic mediators and patient selection in infra-inguinal revascularisation surgery. Int. Angiol. 13(Suppl. 1), 51 (1994).
71. Clark P, Wu O: ABO(H) blood groups and pre-eclampsia. Thromb. Haemost. 100, 469-474 (2008). Systematic review of ABO(H) and pre-eclampsia syndromes.
72. Amin N, Tahir S, Abadi N: Association of blood groups with preeclamptic toxaemia. Med. Sci. Res. 17, 861-862 (1989).
73. May D: Maternal blood group A and pre-eclampsia. Br. Med. J. 4, 22 (1973).
74. Spinillo A, Capuzzo E, Baltaro F, Piazzi G, Iasci A: Case-control study of maternal blood group and severe pre-eclampsia. J. Hum. Hypertens. 9, 623-625 (1995).
75. Hiltunen L, Laivouri H, Rautanen A et al.: Blood group AB and factor V Leiden as risk factors for pre-eclampsia: a population based nested case-control study. Thromb. Res. 124, 167-173 (2009).
76. Clark P, Meiklejohn D, O'Sullivan A, Vickers M, Greaves M: The relationship of ABO, Lewis and Secretor blood groups with cerebral ischaemia of arterial origin. J. Thromb. Haemost. 3, 2105-2108 (2005). Data on blood group genotypes in stroke.
77. Wiggins K, Smith N, Glazer N et al.: ABO genotype and risk of thrombotic events and hemorrhagic stroke. J. Thromb. Haemost. 7, 263-269 (2009). Data on blood group genotypes in stroke.
78. Ionescu DA, Marcu I, Bicescu E: Cerebral thrombosis, cerebral haemorrhage, and ABO blood-groups. Lancet 1, 278-280 (1976).
79. Bayoumi NA, MacLeod MJ, Greaves M, Vickers MA: ABO blood groups in cerebrovascular accident. Br. J. Haematol. 133(Suppl. 1), 51 (2006).
80. Bronte-Stewart B, Botha M, Krut L: ABO blood groups in relation to ischaemic heart disease. Br. Med. J. I, 1646-1650 (1962).
81. Oliver M, Cumming R: Blood groups and heart disease. Br. Med. J. II, 51 (1962).
82. Allan TM, Dawson AA: ABO blood groups and ischaemic heart disease in men. Br. Heart J. 968, 377-382 (1968).
83. Maurer R, Hickey N, Mulcahy R: ABO and Rh blood groups in patients with coronary heart disease. Irish J. Med. Sci. 2, 105-108 (1969).
84. Erikssen J, Thaulow E, Stormorken H, Brendemoen O, Hellem A: ABO blood groups and coronary artery disease (CHD): a study in subjects with severe and latent CHD. Thromb. Haemost. 43, 137-140 (1980).
85. Medalie J, Levene C, Papier C et al.: Blood groups, myocardial infarction and angina pectoris among 10,000 adult males. N. Engl. J. Med. 285, 1348-1353 (1971).
86. Suadicani P, Hein HO, Gyntelberg F: Socioeconomic status, ABO phenotypes and risk ischaemic heart disease: an 8 year follow-up in the Copenhagen Male study. J. Cardiovasc. Risk 7, 277-283 (2000).
87. Anvari M, Boroumand A, Emami B et al.: ABO blood group and coronary artery disease in Iranian patients awaiting coronary bypass graft surgery: a review of 10,641 cases. Lab. Med. 40, 528-530 (2009).
88. Meade T, Cooper J, Stirling Y. Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br. J. Haematol. 88, 601-607 (1994).
89. Whincup P, Cook D, Phillips A, Shaper A: ABO blood groups and ischaemic heart disease in British men. Br. Med. J. 300, 1679-1682 (1990).
90. Roest M, Voorbij H, Baredrecht A, Peeters P, van der Schouw Y: Risk of acute ischemic heart disease in postmenopausal women depends on von Willebrand factor and fibrinogen concentrations and blood group genotype. J. Thromb. Haemost. 5, 189-191 (2007). First study reporting potential utility of ABO(H) in arterial disease screening.
91. Royal College of Obstetricians and Gynaecologists (RCOG): Green-top guideline No 37. Reducing the risk of thrombosis and embolism during pregnancy and the puerperium. RCOG, London, UK (2009). Recent UK guideline detailing the factors (although not blood group) to be considered in the prevention of pregnancy-associated VTE.
92. Clark P, Bates S: North American and British guidelines for anti-thrombotic therapy: are we reaching consensus? Thromb. Res. 123(Suppl. 2), S111-S123 (2009). Review of international guidelines of thromboprophylaxis in pregnancy.
93. Robertson L, Wu O, Langhorne P et al.: Thrombophilia in pregnancy: a systematic review. Br. J. Haematol. 132, 171-196 (2005). Comprehensive systematic review of thrombophilia in pregnancy.
94. Jick H, Slone D, Westerholm B et al.: Venous thromboembolic disease and ABO blood type. A cooperative study. Lancet 1, 539-542 (1969).
95. Larsen TB, Johnsen SP, Gislum M, Moller CA, Larsen H, Sorensen HT: ABO blood groups and risk of venous thromboembolism during pregnancy and the puerperium. A population-based, nested case-control study. J. Thromb. Haemost. 3, 300-304 (2005).
96. Clark P, Twaddle S, Walker ID, Scott L, Greer IA: Cost-effectiveness of screening for the factor V Leiden mutation in pregnant women. Lancet 359, 1919-1920 (2002). Report on the cost-effectiveness of screening for FVL in pregnancy.
97. Carter Y, Caps M, Meissner M: Deep venous thrombosis and ABO blood group are unrelated in trauma patients. J. Trauma Injury Infect. Crit. Care 52, 112-116 (2002).
98. Wu O, Robertson L, Twaddle S et al.: Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol. Assess. 10 (11), (2006). Comprehensive systematic review and cost-effectiveness analysis of thrombophilia in a variety of high-risk clinical scenarios.